Interpace Biosciences Inc (IDXG) NPV
Sell:$1.26Buy:$1.26
$0.01
(0.80%)
- This stock can be held in a
Stocks and Shares ISA
Fund and Share Account$0.01
(0.80%)$0.01
(0.80%)Company Information
About this company
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.
Key people
Key facts
- EPIC-
- LocationUnited States
- SectorHealthcare
- IndustryHealthcare Facilities
- ISINUS46062X3035
- Market cap$5.20m
- Employees108
- Shares in issue4.53m
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.